Metastatic prostate cancer cases ballooned in the last decade

Metastatic prostate cancer cases ballooned in the last decade

Shared by:

Over the past decade, the number of incidences of metastatic prostate cancer has shot up by 72 percent, scientists report. This alarming statistic, to be published in Nature’s Prostate Cancer and Prostatic Diseases journal, should catalyze the re-assessment of current screening and testing practice
23 Jul 2016 - General
In my country, prostate specific antigen is not freely available in the government sector. It is a quite expensive investigation to do at a private laboratory so most of the people from lower to middle-income social background cannot afford it. Same goes with transrectal ultrasound scans. Its availability in the government hospitals is limited due to high demand. Therefor routine screening of prostate cancer with PSA/USS is practically impossible to do. In my opinion a more practice alternative ...
 (Total 128 words)
Screening methods for cancer a wrought with the problem of detecting unnecessary cancers which would otherwise have remained silent in the patient throughout his lifetime. Making a 'patient' out of an unsuspecting and otherwise healthy behaviour is really a hazard of screening that has to be dealt with because of the tremendous benefits which screening has.
A similar problem is seen in screening for breast cancer and Ductal carcinoma in-situ or DCIS is almost entirely a disease which...
 (Total 171 words)
We are back to the old question and debate. Do we do Prostate specific antigen or not to do prostate specific antigen. The normal value of PSA is 0 to 4.0 ng/mL; above 20 ng/mL there is 70% chance of cancer, while a value of
4-20 ng/mL has a chance of 20-30% of cancer. (Sim & Cheng, 2003). However, 20–25% of patients with carcinoma of the prostate have a PSA level less than 4 ng/mL – which was the accepted ‘normal’ value in the past. Transrectal ultrasound (TRUS) examination and biopsy a...
 (Total 150 words)